Clinical trials: Myocardial Infarct
Myocardial Infarction
Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack
The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).
- Trial name
- NCT01539590
- Testing
- BB3, Normal saline
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Angion Biomedica Corp
Myocardial Infarction
Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)
Stress, anger and depressed can operate as a trigger to an Acute Coronary Syndrome. It is often found in the literature that patients refer excessive anger, anxiety, sadness, pain or acute stress before the acute myocardial…
- Trial name
- MAPAMI (NCT02868216)
- Testing
- anger management training
- Volunteers
- 90 people
- Sponsor
- Instituto de Cardiologia do Rio Grande do Sul
Cardiovascular Disease
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
- Trial name
- CARES (NCT01101035)
- Testing
- Febuxostat, Allopurinol
- Where
- 203 sites in United States, Mexico
- Volunteers
- 6,198 people
- Sponsor
- Takeda
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12…
- Trial name
- GEMINI ACS 1 (NCT02293395)
- Testing
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel
- Where
- 259 sites in United States, Argentina and 18 more
- Volunteers
- 3,037 people
- Sponsor
- Janssen Research & Development, LLC
Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation
ACCESS to the Cardiac Cath Lab in Patients Without STEMI Resuscitated From Out-of-hospital VT/VF Cardiac Arrest
To determine if survival to hospital discharge with good neurological outcome for adults ages 18-75 who are resuscitated from out-of-hospital VT/VF cardiac arrest without clinical signs of a heart attack do better by going…
- Conditions
- Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation, Cardiopulmonary Arrest With Successful Resuscitation
- Trial name
- NCT03119571
- Testing
- Initial CCL admission, Initial ICU admission
- Where
- 23 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- University of Minnesota
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)
Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
The goal of this proposal is to test the implementation of an innovative approach to improving health and lowering cost for a high risk population of patients with acute myocardial infarction (AMI) immediately…
- Trial name
- Heartstrong (NCT01800201)
- Testing
- Electronic Pill Bottle, Incentives, Social Influence
- Where
- United States
- Volunteers
- 1,509 people
- Sponsor
- University of Pennsylvania
Acute Coronary Syndrome, Myocardial Infarction
Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography
The growing availability of cardiac computed tomography (CT)* in emergency departments (EDs) across the U.S. expands the opportunities for its clinical application, but also heightens the need to define its appropriate use in the…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina Pectoris
- Trial name
- ROMICAT-II (NCT01084239)
- Testing
- Cardiac Computed Tomography
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndrome, Myocardial Infarction
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
The goal of this clinical trial is to compare implementation of a Decision Support System (DSS) - aligned to the 2019 ESC/EAS Guidelines - in addition to routine clinical care versus routine clinical care without availability of…
- Trial name
- ZODIAC (NCT05844566)
- Testing
- Decision Support System (DSS)
- Where
- 42 sites in Italy, Spain and 1 more
- Volunteers
- 1,139 people
- Sponsor
- Imperial College London
Coronary Artery Disease, Myocardial Infarction
Colchicine Cardiovascular Outcomes Trial (COLCOT)
The study evaluates whether long-term treatment with colchicine reduces rates of cardiovascular events in patients after myocardial infarction.
- Trial name
- COLCOT (NCT02551094)
- Testing
- colchicine
- Where
- Canada
- Volunteers
- 4,745 people
- Sponsor
- Montreal Heart Institute
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Post Procedural Myocardial Infarction
Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
This study investigates the cardioprotective effect of remote ischaemic pre-/postconditioning in patients presenting with a NSTEMI/Unstable angina undergoing PCI.
- Trial name
- NCT03726164
- Testing
- Remote Conditioning
- Volunteers
- 626 people
- Sponsor
- University College, London
Non ST-elevation Myocardial Infarction
Brilinta Taiwan Post Approval Safety Study
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the…
- Trial name
- NCT02406248
- Testing
- Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
- Where
- 13 sites in Taiwan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation
Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
The aim of the study is to prove that early discharge (within 72 hours) in selected group of patients after myocardial infarction with elevations of ST-segment is feasible and safe
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation, Primary Percutaneous Coronary Intervention, Early Discharge
- Trial name
- NCT02023983
- Testing
- Early discharge, Standard discharge
- Where
- Czechia
- Volunteers
- 151 people
- Sponsor
- Kamil Novobílský
Myocardial Infarction, Cardiovascular Disease
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the…
- Trial name
- SECURE (NCT02596126)
- Testing
- Cardiovascular Polypill, Treatment Prevention for Secondary CV
- Where
- 113 sites in Czechia, France and 5 more
- Volunteers
- 2,499 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Myocardial Infarction, Hypercholesterolemia
Alirocumab in Patients With Acute Myocardial Infarction
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in…
- Trial name
- NCT02938949
- Testing
- alirocumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline